Nitric oxide-dependent efflux of cGMP in rat cerebellar cortex: an in vivo microdialysis study.
The stimulation of excitatory amino acid receptors in the cerebellar cortex results in the Ca2+/calmodulin-dependent activation of nitric oxide synthase. This leads to an increase in tissue levels of cGMP following the interaction of nitric oxide with soluble guanylyl cyclase. The cerebellar cortex has the highest levels of nitric oxide synthase and cGMP in the brain; however, the levels of guanylyl cyclase and cGMP-phosphodiesterase are remarkably low. Thus, the mechanisms regulating cGMP levels in cerebellar cells are unclear. One report has noted that cGMP can be released from cerebellar slices. We have therefore used intracerebellar microdialysis in awake, freely moving rats to test the hypothesis that activation of nitric oxide synthase in the cerebellar cortex results in the release of cGMP. Climbing fibers, which release excitatory amino acids in the cerebellum, were activated with systemic harmaline. This resulted in an immediate increase in extracellular cGMP, which was blocked by TTX or the removal of extracellular Ca2+, and attenuated by prior lesion of the climbing fibers. Blockade of N-type calcium channels with omega-conotoxin also antagonized the harmaline-induced increase. In contrast, blockade of L-type calcium channels, or inhibition of anion transport with probenecid or bromosulfophthalein, potentiated the increase in cGMP seen in response to harmaline. Inhibitors of nitric oxide synthase or guanylyl cyclase prevented the harmaline-induced increase in extracellular cGMP, while phosphodiesterase inhibitors potentiated the increase. Local application of the NMDA antagonist 2-amino-5-phosphonopentanoic acid or the AMPA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione attenuated the effect of harmaline.(ABSTRACT TRUNCATED AT 250 WORDS)
Luo
D
D
Kinsmen Laboratory of Neurological Sciences, Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Leung
E
E
Vincent
S R
SR
D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors; D000596:Amino Acids / Q000502:physiology; D000818:Animals; D002525:Cerebellar Cortex / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D005110:Extracellular Space / Q000378:metabolism; D006246:Harmaline / Q000494:pharmacology; D008297:Male; D017551:Microdialysis; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019001:Nitric Oxide Synthase; D051381:Rats; D017208:Rats, Wistar; D013268:Stimulation, Chemical
D000596:Amino Acids; D009569:Nitric Oxide; D006246:Harmaline; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases; D006152:Cyclic GMP